| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10646572 | ACCORD | Pharmaceutical compositions with enhanced stability |
Jan, 2027
(2 years from now) | |
| US9744207 | ACCORD | Pharmaceutical compositions with enhanced stability |
Jan, 2027
(2 years from now) | |
| US9572857 | ACCORD | Pharmaceutical compositions with enhanced stability |
Jan, 2027
(2 years from now) | |
| US11717555 | ACCORD | Pharmaceutical compositions having a selected release duration |
Jan, 2039
(14 years from now) | |
Camcevi Kit is owned by Accord.
Camcevi Kit contains Leuprolide Mesylate.
Camcevi Kit has a total of 4 drug patents out of which 0 drug patents have expired.
Camcevi Kit was authorised for market use on 25 May, 2021.
Camcevi Kit is available in emulsion;subcutaneous dosage forms.
The generics of Camcevi Kit are possible to be released after 01 January, 2039.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | May 25, 2024 |
Drugs and Companies using LEUPROLIDE MESYLATE ingredient
Market Authorisation Date: 25 May, 2021
Treatment: NA
Dosage: EMULSION;SUBCUTANEOUS
More Information on Dosage
CAMCEVI KIT family patents
